98%
921
2 minutes
20
Background: Gait deficits and leg spasticity are frequent symptoms in Primary and Secondary Progressive Multiple Sclerosis (PPMS and SPMS). Transcutaneous spinal cord stimulation (tSCS) may alleviate these symptoms through the reduction of spinal hyperexcitability. We conducted a single-center, randomized, sham-controlled clinical crossover study (German Clinical Trials Register: DRKS00023357, https://www.drks.de/search/en) in patients with PPMS and SPMS to assess the therapy effects of tSCS on spasticity and gait in the post stimulation period.
Methods: Twenty participants were included in the study to receive tSCS and sham interventions on two separate study days in randomized order. Patients and examiners were blinded to the sequence allocation, which was performed using a quasi-randomized procedure to ensure balanced group sizes. The tSCS intervention consisted of biphasic pulses applied for 30 min at 50 Hz to lumbar spinal segments. Assessments were carried out before and immediately after each intervention. The primary outcome was defined as the Modified Ashworth Scale (MAS) sum score for bilateral leg spasticity. Secondary outcomes included unilateral MAS sum scores and clinical gait assessments. We used inertial sensors to monitor gait kinematics and EMG to record Posterior-Root-Muscle-Reflexes (PRM-reflex) in leg muscles.
Results: Following the exclusion of two dropouts and two participants who did not reach the target intensity, sixteen participants, evenly distributed across the two intervention sequences, were included in the analysis. In comparison to sham, tSCS had a small effect on bilateral MAS sum score (effect size = -0.25, p = 0.12, CI: -5.67-0.63, for Generalized Equation Estimation), which didn't reach significance. More patients showed an improvement in stimulation condition (10 out of 16 patients) than in sham condition (7 out of 16 patients). We observed negligible effects of tSCS on clinical gait tests, kinematic parameters and PRM-reflex recruitment.
Conclusion: Our results showed that tSCS had a small but no significant effect on spasticity. A reduction of spasticity did not immediately translate into an improvement of gait performance.
Clinical Trials Registration: https://www.drks.de/search/en, identifier: DRKS00023357.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12408504 | PMC |
http://dx.doi.org/10.3389/fneur.2025.1618519 | DOI Listing |
Front Neurol
August 2025
Department of Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Background: Gait deficits and leg spasticity are frequent symptoms in Primary and Secondary Progressive Multiple Sclerosis (PPMS and SPMS). Transcutaneous spinal cord stimulation (tSCS) may alleviate these symptoms through the reduction of spinal hyperexcitability. We conducted a single-center, randomized, sham-controlled clinical crossover study (German Clinical Trials Register: DRKS00023357, https://www.
View Article and Find Full Text PDFJMIR Res Protoc
August 2025
Hunan Provincial Hospital of Integrated Traditional Chinese and Western Medicine (Hunan Academy of Chinese Medicine Affiliated Hospital), Changsha, China.
Background: Poststroke spasticity (PSS) is a frequent sequela in patients who have experienced stroke. This form of paralysis is more prevalent compared to other poststroke sequelae and is among the most challenging and complex symptoms to manage. Surface electromyography (sEMG) can reflect the physiological information of muscles in real time and is highly beneficial in diagnosing neuromuscular diseases in clinical medicine.
View Article and Find Full Text PDFScand J Med Sci Sports
July 2025
Institute of Cardiology and Sports Medicine, German Sport University Cologne, Cologne, Germany.
Here, we assessed the prevalence of post-COVID-condition (PCC, also known as long-COVID) and investigated its associations with health-related quality of life and immune-related biomarkers in track and field masters athletes (MAs). A total of 216 MAs (114 males, 102 females; age: 58.3 ± 11.
View Article and Find Full Text PDFNPJ Digit Med
June 2025
Roche Pharma Research and Early Development (pRED) Neuroscience & Rare Diseases, Data & Analytics, Pharmaceutical Sciences, Clinical Pharmacology, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Digital health technology (DHT) tools for Parkinson's disease (PD) e.g., smartphones and wearables were used for remote and frequent measurement of motor signs in the phase 2 PASADENA study of the anti-alpha-synuclein monoclonal antibody prasinezumab.
View Article and Find Full Text PDFACS Nano
June 2025
School of Materials Science and Engineering, Nanyang Technological University, 50 Nanyang Ave, Singapore 639798, Singapore.
Although hybrid perovskite-based devices have made significant advances in terms of device performance, long-term stability remains a major challenge to widespread implementation. A unified understanding of the complexity describing the degradation of these types of materials is absent, and in this work, one common hybrid perovskite material, methylammonium lead iodide (MAPI), is used as a vehicle to show how a unified understanding can be achieved using complementary characterization techniques. This work uses low-dose electron microscopes with electric fields ranging from 2.
View Article and Find Full Text PDF